This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sheu, T. G.
Right arrow Articles by Gubareva, L. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sheu, T. G.
Right arrow Articles by Gubareva, L. V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3284-3292, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00555-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008{triangledown}

Tiffany G. Sheu, Varough M. Deyde, Margaret Okomo-Adhiambo, Rebecca J. Garten, Xiyan Xu, Rick A. Bright,{dagger} Eboneé N. Butler, Teresa R. Wallis, Alexander I. Klimov, and Larisa V. Gubareva*

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333

Received 29 April 2008/ Returned for modification 23 May 2008/ Accepted 3 July 2008

The surveillance of seasonal influenza virus susceptibility to neuraminidase (NA) inhibitors was conducted using an NA inhibition assay. The 50% inhibitory concentration values (IC50s) of 4,570 viruses collected globally from October 2004 to March 2008 were determined. Based on mean IC50s, A(H3N2) viruses (0.44 nM) were more sensitive to oseltamivir than A(H1N1) viruses (0.91 nM). The opposite trend was observed with zanamivir: 1.06 nM for A(H1N1) and 2.54 nM for A(H3N2). Influenza B viruses exhibited the least susceptibility to oseltamivir (3.42 nM) and to zanamivir (3.87 nM). To identify potentially resistant viruses (outliers), a threshold of a mean IC50 value + 3 standard deviations was defined for type/subtype and drug. Sequence analysis of outliers was performed to identify NA changes that might be associated with reduced susceptibility. Molecular markers of oseltamivir resistance were found in six A(H1N1) viruses (H274Y) and one A(H3N2) virus (E119V) collected between 2004 and 2007. Some outliers contained previously reported mutations (e.g., I222T in the B viruses), while other mutations [e.g., R371K and H274Y in B viruses and H274N in A(H3N2) viruses) were novel. The R371K B virus outlier exhibited high levels of resistance to both inhibitors (>100 nM). A substantial variance at residue D151 was observed among A(H3N2) zanamivir-resistant outliers. The clinical relevance of newly identified NA mutations is unknown. A rise in the incidence of oseltamivir resistance in A(H1N1) viruses carrying the H274Y mutation was detected in the United States and in other countries in the ongoing 2007 to 2008 season. As of March 2008, the frequency of resistance among A(H1N1) viruses in the United States was 8.6% (50/579 isolates). The recent increase in oseltamivir resistance among A(H1N1) viruses isolated from untreated patients raises public health concerns and necessitates close monitoring of resistance to NA inhibitors.

* Corresponding author. Mailing address: 1600 Clifton Rd. NE, MS G-16, Atlanta, GA 30033. Phone: (404) 639-3204. Fax: (404) 639-0800. E-mail: LGubareva{at}cdc.gov

{triangledown} Published ahead of print on 14 July 2008.

{dagger} Present address: PATH, 1800 K Street NW, Suite 800, Washington, DC 20006.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3284-3292, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00555-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Khazeni, N., Bravata, D. M., Holty, J.-E. C., Uyeki, T. M., Stave, C. D., Gould, M. K. (2009). Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. ANN INTERN MED 151: 464-473 [Abstract] [Full Text]  
  • Nguyen, J. T., Hoopes, J. D., Smee, D. F., Prichard, M. N., Driebe, E. M., Engelthaler, D. M., Le, M. H., Keim, P. S., Spence, R. P., Went, G. T. (2009). Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro. Antimicrob. Agents Chemother. 53: 4115-4126 [Abstract] [Full Text]  
  • Hurt, A. C., Holien, J. K., Barr, I. G. (2009). In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses. Antimicrob. Agents Chemother. 53: 4433-4440 [Abstract] [Full Text]  
  • Shinde, V., Bridges, C. B., Uyeki, T. M., Shu, B., Balish, A., Xu, X., Lindstrom, S., Gubareva, L. V., Deyde, V., Garten, R. J., Harris, M., Gerber, S., Vagasky, S., Smith, F., Pascoe, N., Martin, K., Dufficy, D., Ritger, K., Conover, C., Quinlisk, P., Klimov, A., Bresee, J. S., Finelli, L. (2009). Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005-2009. NEJM 360: 2616-2625 [Abstract] [Full Text]  
  • Fleming, D. M., Elliot, A. J., Meijer, A., Paget, W. J. (2009). Influenza virus resistance to oseltamivir: what are the implications?. Eur J Public Health 19: 238-239 [Full Text]  
  • Tamura, D., Mitamura, K., Yamazaki, M., Fujino, M., Nirasawa, M., Kimura, K., Kiso, M., Shimizu, H., Kawakami, C., Hiroi, S., Takahashi, K., Hata, M., Minagawa, H., Kimura, Y., Kaneda, S., Sugita, S., Horimoto, T., Sugaya, N., Kawaoka, Y. (2009). Oseltamivir-Resistant Influenza A Viruses Circulating in Japan. J. Clin. Microbiol. 47: 1424-1427 [Abstract] [Full Text]  
  • Van Hoeven, N., Belser, J. A., Szretter, K. J., Zeng, H., Staeheli, P., Swayne, D. E., Katz, J. M., Tumpey, T. M. (2009). Pathogenesis of 1918 Pandemic and H5N1 Influenza Virus Infections in a Guinea Pig Model: Antiviral Potential of Exogenous Alpha Interferon To Reduce Virus Shedding. J. Virol. 83: 2851-2861 [Abstract] [Full Text]  
  • Dharan, N. J., Gubareva, L. V., Meyer, J. J., Okomo-Adhiambo, M., McClinton, R. C., Marshall, S. A., St. George, K., Epperson, S., Brammer, L., Klimov, A. I., Bresee, J. S., Fry, A. M., for the Oseltamivir-Resistance Working Group, (2009). Infections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States. JAMA 301: 1034-1041 [Abstract] [Full Text]  
  • Weinstock, D. M., Zuccotti, G. (2009). The Evolution of Influenza Resistance and Treatment. JAMA 301: 1066-1069 [Full Text]  
  • Deyde, V. M., Nguyen, T., Bright, R. A., Balish, A., Shu, B., Lindstrom, S., Klimov, A. I., Gubareva, L. V. (2009). Detection of Molecular Markers of Antiviral Resistance in Influenza A (H5N1) Viruses Using a Pyrosequencing Method. Antimicrob. Agents Chemother. 53: 1039-1047 [Abstract] [Full Text]  
  • Baz, M., Abed, Y., Nehme, B., Boivin, G. (2009). Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. Antimicrob. Agents Chemother. 53: 791-793 [Abstract] [Full Text]  
  • MOSSAD, S. B. (2008). 2008-2009 Influenza update: A better vaccine match. Cleveland Clinic Journal of Medicine 75: 865-870 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»